{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:11:24Z","timestamp":1792098684769,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970815"],"award-info":[{"award-number":["81970815"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00417-020-04988-y","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T16:02:47Z","timestamp":1604505767000},"page":"1455-1462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["One-year results of intravitreal conbercept in treatment-na\u00efve subjects with polypoidal choroidal vasculopathy"],"prefix":"10.1007","volume":"259","author":[{"given":"Lin-Hong","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian Yat Hin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Feng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4162-5918","authenticated-orcid":false,"given":"Xiao-Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"issue":"1","key":"4988_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","volume":"10","author":"LA Yannuzzi","year":"1990","unstructured":"Yannuzzi LA, Sorenson J, Spaide RF, Lipson B (1990) Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina (Philadelphia, Pa) 10(1):1\u20138","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"6","key":"4988_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.survophthal.2010.03.004","volume":"55","author":"Y Imamura","year":"2010","unstructured":"Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA (2010) Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol 55(6):501\u2013515. https:\/\/doi.org\/10.1016\/j.survophthal.2010.03.004","journal-title":"Surv Ophthalmol"},{"issue":"8","key":"4988_CR3","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.ophtha.2009.12.018","volume":"117","author":"LH Lima","year":"2010","unstructured":"Lima LH, Schubert C, Ferrara DC, Merriam JE, Imamura Y, Freund KB, Spaide RF, Yannuzzi LA, Allikmets R (2010) Three major loci involved in age-related macular degeneration are also associated with polypoidal choroidal vasculopathy. Ophthalmology 117(8):1567\u20131570. https:\/\/doi.org\/10.1016\/j.ophtha.2009.12.018","journal-title":"Ophthalmology"},{"issue":"4","key":"4988_CR4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/IAE.0b013e31826af540","volume":"33","author":"SE Chung","year":"2013","unstructured":"Chung SE, Kang SW, Kim JH, Kim YT, Park DY (2013) Engorgement of vortex vein and polypoidal choroidal vasculopathy. Retina (Philadelphia, Pa) 33(4):834\u2013840. https:\/\/doi.org\/10.1097\/IAE.0b013e31826af540","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"8","key":"4988_CR5","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1097\/IAE.0b013e3182953df4","volume":"33","author":"DJ Warrow","year":"2013","unstructured":"Warrow DJ, Hoang QV, Freund KB (2013) Pachychoroid pigment epitheliopathy. Retina (Philadelphia, Pa) 33(8):1659\u20131672. https:\/\/doi.org\/10.1097\/IAE.0b013e3182953df4","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"1","key":"4988_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","volume":"33","author":"CMG Cheung","year":"2019","unstructured":"Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB (2019) Pachychoroid disease. Eye 33(1):14\u201333. https:\/\/doi.org\/10.1038\/s41433-018-0158-4","journal-title":"Eye"},{"key":"4988_CR7","doi-asserted-by":"publisher","unstructured":"Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 148 (1):43-58.e41. https:\/\/doi.org\/10.1016\/j.ajo.2009.01.024","DOI":"10.1016\/j.ajo.2009.01.024"},{"issue":"2","key":"4988_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4103\/tjo.tjo_35_18","volume":"9","author":"AH Palkar","year":"2019","unstructured":"Palkar AH, Khetan V (2019) Polypoidal choroidal vasculopathy: an update on current management and review of literature. Taiwan J Ophthalmol 9(2):72\u201392. https:\/\/doi.org\/10.4103\/tjo.tjo_35_18","journal-title":"Taiwan J Ophthalmol"},{"issue":"8","key":"4988_CR9","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, Weisberger A, Lim TH (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina (Philadelphia, Pa) 32(8):1453\u20131464. https:\/\/doi.org\/10.1097\/IAE.0b013e31824f91e8","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"11","key":"4988_CR10","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh A, Lai TYY, Takahashi K, Wong TY, Chen L-J, Ruamviboonsuk P, Tan CS, Feller C, Margaron P, Lim TH, Lee WK (2017) Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA ophthalmology 135(11):1206\u20131213. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.4030","journal-title":"JAMA ophthalmology"},{"issue":"4","key":"4988_CR11","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ajo.2013.05.024","volume":"156","author":"A Oishi","year":"2013","unstructured":"Oishi A, Kojima H, Mandai M, Honda S, Matsuoka T, Oh H, Kita M, Nagai T, Fujihara M, Bessho N, Uenishi M, Kurimoto Y, Negi A (2013) Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am J Ophthalmol 156(4):644\u2013651. https:\/\/doi.org\/10.1016\/j.ajo.2013.05.024","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"4988_CR12","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/bjo.2007.135103","volume":"92","author":"TY Lai","year":"2008","unstructured":"Lai TY, Chan WM, Liu DT, Luk FO, Lam DS (2008) Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 92(5):661\u2013666. https:\/\/doi.org\/10.1136\/bjo.2007.135103","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"4988_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/iae.0000000000002035","volume":"39","author":"Z Huang","year":"2019","unstructured":"Huang Z, Ding Q, Yan M, Lian H, Chen Z, Chen X, Song Y (2019) Short-term efficacy of conbercept and ranibizumab for polypoidal choroidal vasculopathy. Retina (Philadelphia, Pa) 39(5):889\u2013895. https:\/\/doi.org\/10.1097\/iae.0000000000002035","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"9","key":"4988_CR14","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.ophtha.2015.05.024","volume":"122","author":"A Yamamoto","year":"2015","unstructured":"Yamamoto A, Okada AA, Kano M, Koizumi H, Saito M, Maruko I, Sekiryu T, Iida T (2015) One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology 122(9):1866\u20131872. https:\/\/doi.org\/10.1016\/j.ophtha.2015.05.024","journal-title":"Ophthalmology"},{"issue":"5","key":"4988_CR15","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1097\/iae.0000000000000875","volume":"36","author":"J Qu","year":"2016","unstructured":"Qu J, Cheng Y, Li X, Yu L, Ke X (2016) efficacy of intravitreal injection of conbercept in polypoidal choroidal vasculopathy: subgroup analysis of the Aurora study. Retina (Philadelphia, Pa) 36(5):926\u2013937. https:\/\/doi.org\/10.1097\/iae.0000000000000875","journal-title":"Retina (Philadelphia, Pa)"},{"key":"4988_CR16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/dddt.S158368","volume":"12","author":"Y Peng","year":"2018","unstructured":"Peng Y, Zhang X, Li M, Liu B, Mi L, Zuo C, Wen F (2018) Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy. Drug Des Devel Ther 12:339\u2013345. https:\/\/doi.org\/10.2147\/dddt.S158368","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"4988_CR17","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, Chen SJ, Wong TY, Mitchell P, Cheung GCM, Zhang Z, Leal S, Ishibashi T, Investigators P (2018) Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol 136(7):786\u2013793. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.1804","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"4988_CR18","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ophtha.2010.08.008","volume":"118","author":"M Zhang","year":"2011","unstructured":"Zhang M, Zhang J, Yan M, Luo D, Zhu W, Kaiser PK, Yu D-C (2011) A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 118(4):672\u2013678. https:\/\/doi.org\/10.1016\/j.ophtha.2010.08.008","journal-title":"Ophthalmology"},{"key":"4988_CR19","doi-asserted-by":"publisher","unstructured":"Qi HJ, Jin EZ, Zhao MW (2019) One-year outcomes of intravitreal conbercept combined rescue therapy for polypoidal choroidal vasculopathy in a Chinese population: a real-life clinical data. Int J Ophthalmol 12 (1):51\u201357. https:\/\/doi.org\/10.18240\/ijo.2019.01.08","DOI":"10.18240\/ijo.2019.01.08"},{"issue":"9","key":"4988_CR20","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.ophtha.2014.03.026","volume":"121","author":"X Li","year":"2014","unstructured":"Li X, Xu G, Wang Y, Xu X, Liu X, Tang S, Zhang F, Zhang J, Tang L, Wu Q, Luo D, Ke X (2014) Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology 121(9):1740\u20131747. https:\/\/doi.org\/10.1016\/j.ophtha.2014.03.026","journal-title":"Ophthalmology"},{"key":"4988_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ajo.2016.12.008","volume":"177","author":"EW Chan","year":"2017","unstructured":"Chan EW, Eldeeb M, Lingam G, Thomas D, Bhargava M, Chee CK (2017) Quantitative changes in pigment epithelial detachment area and volume predict retreatment in polypoidal choroidal vasculopathy. Am J Ophthalmol 177:195\u2013205. https:\/\/doi.org\/10.1016\/j.ajo.2016.12.008","journal-title":"Am J Ophthalmol"},{"key":"4988_CR22","doi-asserted-by":"publisher","unstructured":"Tsujikawa A, Sasahara M, Otani A, Gotoh N, Kameda T, Iwama D, Yodoi Y, Tamura H, Mandai M, Yoshimura N (2007) Pigment epithelial detachment in polypoidal choroidal vasculopathy. American journal of ophthalmology 143 (1):102\u2013111.e101. https:\/\/doi.org\/10.1016\/j.ajo.2006.08.025","DOI":"10.1016\/j.ajo.2006.08.025"},{"issue":"2","key":"4988_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3341\/kjo.2011.25.2.98","volume":"25","author":"JB Chae","year":"2011","unstructured":"Chae JB, Lee JY, Yang SJ, Kim J-G, Yoon YH (2011) Time-lag between subretinal fluid and pigment epithelial detachment reduction after polypoidal choroidal vasculopathy treatment. Korean J Ophthalmol 25(2):98. https:\/\/doi.org\/10.3341\/kjo.2011.25.2.98","journal-title":"Korean J Ophthalmol"},{"issue":"7","key":"4988_CR24","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.4103\/ijo.IJO_638_18","volume":"67","author":"SR Singh","year":"2019","unstructured":"Singh SR, Sahoo NK, Goud NR, Chhablani J (2019) Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy. Indian J Ophthalmol 67(7):1114\u20131118. https:\/\/doi.org\/10.4103\/ijo.IJO_638_18","journal-title":"Indian J Ophthalmol"},{"key":"4988_CR25","doi-asserted-by":"publisher","unstructured":"de Oliveira Dias JR, de Andrade GC, Novais EA, Farah ME, Rodrigues EB (2016) Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. International Journal of Retina and Vitreous 2. https:\/\/doi.org\/10.1186\/s40942-016-0026-y","DOI":"10.1186\/s40942-016-0026-y"},{"key":"4988_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","volume":"204","author":"TY Wong","year":"2019","unstructured":"Wong TY, Ogura Y, Lee WK, Iida T, Chen SJ, Mitchell P, Gemmy Cheung CM, Zhang Z, Leal S, Ishibashi T, Investigators P (2019) Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: two-year results of the aflibercept in polypoidal choroidal vasculopathy study. Am J Ophthalmol 204:80\u201389. https:\/\/doi.org\/10.1016\/j.ajo.2019.02.027","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"4988_CR27","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/bjophthalmol-2018-312419","volume":"103","author":"N Miyamoto","year":"2019","unstructured":"Miyamoto N, Mandai M, Oishi A, Nakai S, Honda S, Hirashima T, Oh H, Matsumoto Y, Uenishi M, Kurimoto Y (2019) Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study. Br J Ophthalmol 103(6):844\u2013848. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312419","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"4988_CR28","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1097\/iae.0000000000000229","volume":"34","author":"M Inoue","year":"2014","unstructured":"Inoue M, Arakawa A, Yamane S, Kadonosono K (2014) Short-term efficacy of intravitreal aflibercept in treatment-naive patients with polypoidal choroidal vasculopathy. Retina (Philadelphia, Pa) 34(11):2178\u20132184. https:\/\/doi.org\/10.1097\/iae.0000000000000229","journal-title":"Retina (Philadelphia, Pa)"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04988-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-020-04988-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04988-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T10:15:21Z","timestamp":1622456121000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-020-04988-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["4988"],"URL":"https:\/\/doi.org\/10.1007\/s00417-020-04988-y","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,4]]},"assertion":[{"value":"28 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there are no conflicts of interest regarding the publication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study adhered to the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of People\u2019s Hospital of Peking University. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}